Abstract
Glucose-phosphorylating enzyme, glucokinase (GK) plays a major role in glucose homeostasis primarily through its regulatory actions in pancreatic β-cells and liver hepatocytes. Conversion of glucose to glucose-6-phosphate by GK promotes glycogen synthesis in liver hepatocytes, and insulin release in the pancreatic β-cells. Small molecules called glucokinase activators (GKAs) which bind to an allosteric activator site of the GK enzyme have indeed been discovered and developed, and thus hold great promise as new, effective and safe antidiabetic agents. GKAs enhance the catalytic activity of GK and promising clinical trials in humans demonstrated that they are highly useful in the treatment of type 2 diabetes mellitus. Most of the reported GKAs include amide derivatives like benzamides, acrylamides, carboxamides, acetamides and acrylamides. Examples include Piragliatin, AZD1656, AZD6370, R1440 GKA2, GKA 50, YH GKA, PSN 010, and LY2121260. Recent findings on GKAs including lead compounds and overview of current hypothesis on mechanism of GK activation along with summary of the recently published patents as well as the GKAs of natural origin are reported in the present review.
Keywords: Benzamides, Diabetes mellitus, Glucokinase, Glucokinase activators, T2DM.
Mini-Reviews in Medicinal Chemistry
Title:Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus
Volume: 14 Issue: 7
Author(s): Ajmer Singh Grewal, Bhupinder Singh Sekhon and Viney Lather
Affiliation:
Keywords: Benzamides, Diabetes mellitus, Glucokinase, Glucokinase activators, T2DM.
Abstract: Glucose-phosphorylating enzyme, glucokinase (GK) plays a major role in glucose homeostasis primarily through its regulatory actions in pancreatic β-cells and liver hepatocytes. Conversion of glucose to glucose-6-phosphate by GK promotes glycogen synthesis in liver hepatocytes, and insulin release in the pancreatic β-cells. Small molecules called glucokinase activators (GKAs) which bind to an allosteric activator site of the GK enzyme have indeed been discovered and developed, and thus hold great promise as new, effective and safe antidiabetic agents. GKAs enhance the catalytic activity of GK and promising clinical trials in humans demonstrated that they are highly useful in the treatment of type 2 diabetes mellitus. Most of the reported GKAs include amide derivatives like benzamides, acrylamides, carboxamides, acetamides and acrylamides. Examples include Piragliatin, AZD1656, AZD6370, R1440 GKA2, GKA 50, YH GKA, PSN 010, and LY2121260. Recent findings on GKAs including lead compounds and overview of current hypothesis on mechanism of GK activation along with summary of the recently published patents as well as the GKAs of natural origin are reported in the present review.
Export Options
About this article
Cite this article as:
Grewal Singh Ajmer, Sekhon Singh Bhupinder and Lather Viney, Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus, Mini-Reviews in Medicinal Chemistry 2014; 14 (7) . https://dx.doi.org/10.2174/1389557514666140722082713
DOI https://dx.doi.org/10.2174/1389557514666140722082713 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effect of Stem Cell Transplantation Therapy for Post Viral Chronic Liver Cell Failure on Associated Type II Diabetes Mellitus: A Pilot Study
Endocrine, Metabolic & Immune Disorders - Drug Targets All for Statins and Statins for All; An Update
Current Pharmaceutical Design Treating Diabetes Mellitus in Older and Oldest Old Patients
Current Pharmaceutical Design Role of Glycogen Synthase Kinase-3 in Insulin Resistance and Type 2 Diabetes
Current Drug Targets Relationships Between White Matter Hyperintensities, Cerebral Amyloid Angiopathy and Dementia in a Population-based Sample of the Oldest Old
Current Alzheimer Research Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Dynamics of Telomere Length in Different Age Groups in a Latvian Population
Current Aging Science Anti-Insulin Receptor Antibodies in the Pathology and Therapy of Diabetes Mellitus
Current Diabetes Reviews Atopic Dermatitis in the Elderly
Inflammation & Allergy - Drug Targets (Discontinued) Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms
Current Molecular Medicine The Association between Serum Asymmetric Dimethylarginine and Coronary Atherosclerotic Plaque in an Asymptomatic Population
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Promising Diabetes Therapy Based on the Molecular Mechanism for Glucose Toxicity: Usefulness of SGLT2 Inhibitors as well as Incretin-Related Drugs
Current Medicinal Chemistry Oral L-Carnitine: Metabolite Formation and Hemodialysis
Current Drug Metabolism Targeting α -(1,4)-Glucosidase in Diabetes Mellitus Type 2: The Role of New Synthetic Coumarins as Potent Inhibitors
Current Topics in Medicinal Chemistry Rho-Kinase and RGS-Containing RhoGEFs as Molecular Targets for the Treatment of Erectile Dysfunction
Current Pharmaceutical Design